Xueqing Liu

Xueqing Liu has extensive experience in the pharmaceutical and biosciences industry. They most recently worked at Avidity Biosciences, Inc. as a Principal Scientist starting in February 2022. Prior to that, they served as a Senior Scientist II at Metacrine, Inc. from December 2016 to January 2022. Xueqing Liu also held positions at Intercept Pharmaceuticals, where they worked as a Senior Scientist from September 2015 to November 2016, and as a sr. scientist in an unspecified duration within 2015 to 2016. Additionally, they worked as a Scientist at Regulus Therapeutics from January 2011 to September 2015. At Regulus Therapeutics, Xueqing Liu took on various responsibilities in drug discovery projects, including identifying and validating new drug targets, designing and executing pharmacology studies, and coordinating team members.

Xueqing Liu completed their education with a Doctor of Philosophy (Ph.D.) degree in Biochemistry from Ohio University, where they studied from 1998 to 2003. Following that, from 2003 to 2010, they pursued postdoctoral studies in Metabolic Disease at the University of Wisconsin-Madison. There is no information available regarding their education at Nankai University.